Emerging Markets

Latest Headlines

Latest Headlines

Indian stentmakers gaining global foothold--is U.S. market next?

Companies in India's diamond-cutting district in Surat, Gujurat, are applying their knowledge of lasers to create something else: stents.

India moving closer to implementing price controls on medical devices

The Indian government is forging ahead with its plan to put price controls on medical devices, the most controversial element of an array of reforms designed to bolster the use and manufacture of devices in India.

Lupin antibiotic products banned by Brazil

Lupin, which has been expanding its manufacturing and marketing footprint internationally via M&A, moved on Brazil in May with the acquisition of generics and OTC maker Medquímica Indústria Farmacêutica. But new markets mean new regulations, and the Indian company has been tripped by some issues that led Brazil to ban some of Lupin's antibiotic products.

Chinese staffer key to negotiating deal to bolster FDA staff in China

Vice President Joe Biden weighed in with the Chinese on FDA's efforts to negotiate an agreement to bump up its inspection staff in the country. So did former FDA Commissioner Margaret Hamburg. But it is locally employed FDA staffer Lixia Wang who has won the prize, in part for her efforts to help seal the deal.

Mindray down on the acquisition of remainder of Chinese orthopedics company for $72.6M

Chinese medical device player Mindray Medical was down 7% in early trading on the news that it would acquire the remaining stake of orthopedics player Wuhan Dragonbio Surgical Implant Co. Mindray first gained a controlling stake in Dragonbio for $35.5 million in 2012. Investors may be taking the deal as a sign that a June take-private offer is now off the table. The deal is slated to close this month.

India's Lupin gets Russian production site in deal for Biocom

While recent problems in Russia's economy have thrown some deals off course, Western drugmakers in the last several years have built or bought production capacity in Russia to tap what has been seen as an important emerging market. India's Lupin jumped into that market, picking up a company that will give it a production toehold there.

GSK's ViiV turns to Chinese company for cheap supply of Tivicay API

The HIV-oriented joint venture of Pfizer, GlaxoSmithKline and Japan's Shionogi is turning to a Chinese manufacturer for a cheap supply of dolutegravir, the active ingredient in its Tivicay. The deal is seen as a way to cut the cost in China and some other developing countries of the JV's newest HIV fighter.

J&J's Ethicon sponsors 20+ clinical trials to advance bariatric surgery globally

Ethicon, the Johnson & Johnson unit devoted to surgical tools, is moving to defend its bariatric surgery territory as a slew of noninvasive medical devices to treat obesity line up to gain approval in the U.S. It will spend $3.2 million on more than 20 clinical trials to examine how early surgical intervention can be used to improve conditions such as obesity and Type 2 diabetes.

GSK doubles down on Singapore continuous processing plant

Several years ago, GlaxoSmithKline committed $50 million to set up an antibiotics facility in Singapore to do continuous processing, a radically different manufacturing approach that has a much smaller footprint, and so much lower operating costs and less environmental impact, than traditional batch processing. The drugmaker now says it is ready to embark on a £38 million expansion there.

Broad Institute gets $20M to target TB from Wall Street-led philanthropists

Hedge fund managers are so flush that now they're giving money away. A pair of prominent fund heads have led a collection of wealthy individuals to back a project at the Broad Institute of MIT and Harvard researching the bacteria behind tuberculosis with $20 million. The goal is to better understand the bacteria itself, as well as how drug resistance forms in it and to develop a rapid diagnostic test for drug-resistant TB.